A first patient has been dosed in a Phase 2 trial investigating the safety and long-term efficacy of bryostatin-1 in treating moderate and moderately severe Alzheimer’s disease, the therapy’s developer, Neurotrope, announced. The trial (NCT04538066), which is recruiting patients at several sites across the U.S., will build on data from previous studies assessing bryostatin-1. Specifically, it…
About Alzheimer’s Disease
Walking into a room and forgetting why you went into the room is normal. Walking into a room and forgetting what room you are in is not normal. Alzheimer’s disease is the most common form of dementia and affects one in ten people over the age of 65. Unfortunately, the exact cause of Alzheimer’s disease is not fully understood however leading scientific experts in the field attribute the illness to the irreversible and progressive generalized degeneration of the brain. Alzheimer’s disease goes well beyond the forgetfulness that may accompany aging, and typically first signs include difficulty remembering current information or performing new tasks. Ongoing hallmark symptoms include impaired memory function, difficulty performing everyday tasks, and neurobehavioral abnormalities. Currently, there is no known cure for Alzheimer’s disease, and multi-disciplinary treatment focuses on symptom management and limiting progression.
Conditions
Alzheimer’s News
GemVax Seeks Expanded Access for Mild Alzheimer’s for Planned GV1001 US Trial
GemVax & KAEL has filed for expanded access of its U.S. Food and Drug Administration (FDA) investigational new drug (IND) application for GV1001, its experimental treatment for Alzheimer’s disease. The company is seeking to include additional investigational groups in its clinical development program. The filing comes following positive results of a Phase 2 clinical trial…
Dosing Starts in Phase 2/3 Trial of Athira’s ATH-1017 for Alzheimer’s
Dosing of patients has begun in a Phase 2/3 clinical trial evaluating ATH-1017, Athira Pharma‘s investigational candidate for the treatment of mild to moderate Alzheimer’s disease. “Embarking on this trial to evaluate our new approach to treating Alzheimer’s is the start of a collective experience that will involve not only individuals with Alzheimer’s but their…
Semorinemab Fails to Show Efficacy in Early Alzheimer’s Phase 2 Trial
Semorinemab, a monoclonal antibody against phosphorylated tau, failed to significantly alter dementia’s progression in people with early Alzheimer’s disease (AD) taking part in a Phase 2 clinical trial. The investigational therapy, which is being jointly developed by AC Immune and Genentech (a Roche company), also failed to meet secondary trial goals related to cognition and…
$1.76M Grant to Support Trial of Jotrol, Form of Resveratrol, in Early Alzheimer’s
The National Institute on Aging, a division of the National Institutes of Health, is awarding a $1.76 million, one-year grant to support a Phase 1 clinical trial investigating oral Jotrol as a potential treatment of early stage Alzheimer’s disease. The study is to be called “Safety and Pharmacokinetics of JOTROL for Alzheimer’s Disease.” Further information, including an…
CDC Taps Alzheimer’s Association to Lead National Effort to Slash Dementia Risk
The Alzheimer’s Association has been chosen to lead a national public health effort aimed at lowering the risk of cognitive decline and dementia. The organization was selected by the Centers for Disease Control and Prevention (CDC) as a Building Our Largest Dementia (BOLD) Public Health Center of Excellence (PHCOE) for dementia risk reduction. To fund…
Sumifilam Lowers Levels of Multiple Biomarkers of Disease Activity, Trial Shows
Treatment with sumifilam significantly lowered the levels of multiple biomarkers of disease activity, neurodegeneration, and inflammation in people with mild-to-moderate Alzheimer’s after 28 days of treatment, according to final data from a Phase 2b trial. Sumifilam, Cassava Sciences’ lead investigational candidate for Alzheimer’s disease, also was found to be safe and well-tolerated, and to improve…
Specific Tau Protein Shows Potential as Blood Biomarker in Early Studies
A specific form of the tau protein, called phosphorylated-tau-217 or p-tau217, may function as a blood biomarker of Alzheimer’s disease, allow the development of blood tests to accurately diagnose the disease at earlier stages. These are the findings of three studies presented during the recent Alzheimer’s Association International Conference (AAIC) 2020. The brains of those with Alzheimer’s disease show…
Theme for World Alzheimer’s Month Is ‘Let’s Talk About Dementia’
Events are underway to mark World Alzheimer’s Month, observed every September to raise global awareness about the disease and challenge the stigma regarding dementia. September 21 has been designated World Alzheimer’s Day. Approximately 44 million people worldwide have Alzheimer’s disease, the most common form of dementia and an irreversible progressive neurological disorder. In the U.S., roughly 5.5 million…
Phase 3 Trial of AXS-05 to Treat Agitation in Alzheimer’s Likely by Year’s End
Axsome Therapeutics announced plan to soon open a Phase 3 clinical trial of AXS-05, its investigational oral treatment for Alzheimer’s disease-related agitation, after U.S. Food and Drug Administration (FDA) officials confirmed an earlier study was pivotal. Results from this new efficacy trial, to open before year’s end, are expected to support a new drug application (NDA) seeking…
First Patients Dosed in Annovis Bio’s ANVS401 Trial, Delayed Due to COVID-19
The first three patients have been dosed in a Phase 2a clinical trial investigating Annovis Bio‘s lead compound ANVS401 as a treatment for people with early Alzheimer’s and Parkinson’s diseases, the company said. The trial (NCT04524351) will recruit up to 68 participants at 15 sites scattered across the U.S. Thus far, only the sites in Florida…
Part the Cloud Awards $24M to Researchers Studying Potential Alzheimer’s Treatments
To help accelerate the development of treatments for Alzheimer’s disease, the Alzheimer’s Association’s Part the Cloud research grant program is investing $24 million in clinical trials investigating 16 potential therapies. Scientists from around the world will use the funds to conduct Phase 1 and 2 trials testing a variety of experimental medications and devices. The studies…